Literature DB >> 23608107

Inhibitors for the hepatitis C virus RNA polymerase explored by SAR with advanced machine learning methods.

Iwona E Weidlich1, Igor V Filippov, Jodian Brown, Neerja Kaushik-Basu, Ramalingam Krishnan, Marc C Nicklaus, Ian F Thorpe.   

Abstract

Hepatitis C virus (HCV) is a global health challenge, affecting approximately 200 million people worldwide. In this study we developed SAR models with advanced machine learning classifiers Random Forest and k Nearest Neighbor Simulated Annealing for 679 small molecules with measured inhibition activity for NS5B genotype 1b. The activity was expressed as a binary value (active/inactive), where actives were considered molecules with IC50 ≤0.95 μM. We applied our SAR models to various drug-like databases and identified novel chemical scaffolds for NS5B inhibitors. Subsequent in vitro antiviral assays suggested a new activity for an existing prodrug, Candesartan cilexetil, which is currently used to treat hypertension and heart failure but has not been previously tested for anti-HCV activity. We also identified NS5B inhibitors with two novel non-nucleoside chemical motifs.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23608107      PMCID: PMC3653294          DOI: 10.1016/j.bmc.2013.03.032

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  51 in total

1.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

2.  Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazine.

Authors:  Yuefen Zhou; Stephen E Webber; Douglas E Murphy; Lian-Sheng Li; Peter S Dragovich; Chinh V Tran; Zhongxiang Sun; Frank Ruebsam; Amit M Shah; Mei Tsan; Richard E Showalter; Rupal Patel; Bin Li; Qiang Zhao; Qing Han; Thomas Hermann; Charles R Kissinger; Laurie Lebrun; Maria V Sergeeva; Leo Kirkovsky
Journal:  Bioorg Med Chem Lett       Date:  2008-01-08       Impact factor: 2.823

3.  Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides.

Authors:  Javier de Vicente; Robert T Hendricks; David B Smith; Jay B Fell; John Fischer; Stacey R Spencer; Peter J Stengel; Peter Mohr; John E Robinson; James F Blake; Ramona K Hilgenkamp; Calvin Yee; George Adjabeng; Todd R Elworthy; Jim Li; Beihan Wang; Joe T Bamberg; Seth F Harris; April Wong; Vincent J P Leveque; Isabel Najera; Sophie Le Pogam; Sonal Rajyaguru; Gloria Ao-Ieong; Ludmila Alexandrova; Susan Larrabee; Michael Brandl; Andrew Briggs; Sunil Sukhtankar; Robert Farrell
Journal:  Bioorg Med Chem Lett       Date:  2009-08-08       Impact factor: 2.823

4.  Identification of N,N-disubstituted phenylalanines as a novel class of inhibitors of hepatitis C NS5B polymerase.

Authors:  Laval Chan; T Jagadeeswar Reddy; Mélanie Proulx; Sanjoy K Das; Oswy Pereira; Wuyi Wang; Arshad Siddiqui; Constantin G Yannopoulos; Carl Poisson; Nathalie Turcotte; Alexandre Drouin; M Hicham Alaoui-Ismaili; Richard Bethell; Martine Hamel; Lucille L'Heureux; Darius Bilimoria; Nghe Nguyen-Ba
Journal:  J Med Chem       Date:  2003-04-10       Impact factor: 7.446

5.  Allosteric inhibitors of hepatitis C polymerase: discovery of potent and orally bioavailable carbon-linked dihydropyrones.

Authors:  Hui Li; Angelica Linton; John Tatlock; Javier Gonzalez; Allen Borchardt; Mel Abreo; Tanya Jewell; Leena Patel; Matthew Drowns; Sarah Ludlum; Mike Goble; Michele Yang; Julie Blazel; Ravi Rahavendran; Heather Skor; Stephanie Shi; Cristina Lewis; Shella Fuhrman
Journal:  J Med Chem       Date:  2007-07-21       Impact factor: 7.446

6.  Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109.

Authors:  Shintaro Hirashima; Takayoshi Suzuki; Tomio Ishida; Satoru Noji; Shinji Yata; Izuru Ando; Masakazu Komatsu; Satoru Ikeda; Hiromasa Hashimoto
Journal:  J Med Chem       Date:  2006-07-27       Impact factor: 7.446

7.  Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.

Authors:  Bichitra K Biswal; Meitian Wang; Maia M Cherney; Laval Chan; Constantin G Yannopoulos; Darius Bilimoria; Jean Bedard; Michael N G James
Journal:  J Mol Biol       Date:  2006-06-16       Impact factor: 5.469

8.  Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase.

Authors:  Vincenzo Summa; Alessia Petrocchi; Paola Pace; Victor G Matassa; Raffaele De Francesco; Sergio Altamura; Licia Tomei; Uwe Koch; Philippe Neuner
Journal:  J Med Chem       Date:  2004-01-01       Impact factor: 7.446

9.  Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.

Authors:  Peter S Dragovich; Julie K Blazel; David A Ellis; Qing Han; Ruhi Kamran; Charles R Kissinger; Laurie A LeBrun; Lian-Sheng Li; Douglas E Murphy; Michael Noble; Rupal A Patel; Frank Ruebsam; Maria V Sergeeva; Amit M Shah; Richard E Showalter; Chinh V Tran; Mei Tsan; Stephen E Webber; Leo Kirkovsky; Yuefen Zhou
Journal:  Bioorg Med Chem Lett       Date:  2008-08-29       Impact factor: 2.823

10.  Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency.

Authors:  Pierre L Beaulieu; Michael Bös; Yves Bousquet; Patrick DeRoy; Gulrez Fazal; Jean Gauthier; James Gillard; Sylvie Goulet; Ginette McKercher; Marc-André Poupart; Serge Valois; George Kukolj
Journal:  Bioorg Med Chem Lett       Date:  2004-02-23       Impact factor: 2.823

View more
  7 in total

1.  Development and implementation of (Q)SAR modeling within the CHARMMing web-user interface.

Authors:  Iwona E Weidlich; Yuri Pevzner; Benjamin T Miller; Igor V Filippov; H Lee Woodcock; Bernard R Brooks
Journal:  J Comput Chem       Date:  2014-11-03       Impact factor: 3.376

2.  Improved prediction of drug-target interactions using regularized least squares integrating with kernel fusion technique.

Authors:  Ming Hao; Yanli Wang; Stephen H Bryant
Journal:  Anal Chim Acta       Date:  2016-01-14       Impact factor: 6.558

3.  Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents.

Authors:  Kushagra Kashyap; Mohammad Imran Siddiqi
Journal:  Mol Divers       Date:  2021-07-19       Impact factor: 3.364

4.  Use of big data in drug development for precision medicine: an update.

Authors:  Tongqi Qian; Shijia Zhu; Yujin Hoshida
Journal:  Expert Rev Precis Med Drug Dev       Date:  2019-05-20

5.  Development of Machine Learning Models and the Discovery of a New Antiviral Compound against Yellow Fever Virus.

Authors:  Victor O Gawriljuk; Daniel H Foil; Ana C Puhl; Kimberley M Zorn; Thomas R Lane; Olga Riabova; Vadim Makarov; Andre S Godoy; Glaucius Oliva; Sean Ekins
Journal:  J Chem Inf Model       Date:  2021-07-21       Impact factor: 6.162

6.  Finding candidate drugs for hepatitis C based on chemical-chemical and chemical-protein interactions.

Authors:  Lei Chen; Jing Lu; Tao Huang; Jun Yin; Lai Wei; Yu-Dong Cai
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

7.  Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking.

Authors:  Yu Wei; Jinlong Li; Jie Qing; Mingjie Huang; Ming Wu; Fenghua Gao; Dongmei Li; Zhangyong Hong; Lingbao Kong; Weiqiang Huang; Jianping Lin
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.